Abstract:Although the prognosis of patients with NSCLC Pancoast tumor has traditionally been poor, recent technological advancements have led to significant improvements in the prognosis of these patients. According to a recent clinical trial, the 5-year survival rate of patients treated with tri-modal therapy was about 50%. 4 There are also published data on patients with Pancoast tumors treated with highdose radiotherapy. The results demonstrate that selected patients with Pancoast tumors treated with high-dose inten… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.